I2O Pharma
Developing Oral Delivery of Injectable Drugs
Health Tech & Life Sciences
Non Active, Jan 2018
Company Overview
Snapshot
Founded in December 2011 by Dan Gelvan, I2O Pharma operates with 1–10 employees. The company has secured funding across one round from one investor. In October 2016, I2O Pharma received Seed funding from Aurum Ventures M.K.I.
Business overview
I2O Pharma specializes in the development of oral versions of injectable drugs, leveraging technology licensed from the Hebrew University of Jerusalem. The company's core product strategy focuses on transforming drug delivery methods. I2O Pharma operates within the Health Tech & Life Sciences sector, specifically targeting the Pharmaceuticals market with its drug delivery solutions.
Log in to access full profile ›Company Intelligence Q&A
- Who founded I2O Pharma?
- I2O Pharma was founded by Dan Gelvan.
- When was I2O Pharma founded?
- I2O Pharma was founded in December 2011.
- What is I2O Pharma's primary focus?
- I2O Pharma focuses on developing oral delivery methods for drugs that are typically administered via injection.
- What is the status of I2O Pharma's operations?
- I2O Pharma is currently non-active, as of January 2018.
- Which investor participated in I2O Pharma's Seed funding round?
- In October 2016, I2O Pharma received Seed funding from Aurum Ventures M.K.I.